ROS1 positivity is seen in 1-2% of patients with metastatic lung cancer. Targeted drugs such as crizotinib, lorlatinib, and entrectinib are used in the treatment. We aimed to evaluate the efficacy of crizotinib and the prognosis of patients with ROS1 fusion-positive metastatic non-small cell lung cancer (NSCLC) in this study.
METHODS
We analyzed data of the advanced NSCLC patients with ROS1 mutation retrospectively. We determined
the clinicopathological features of the patients. We evaluated the parameters affecting the prognosis with
survival analyzes.
RESULTS
The research enlisted the participation of 21 patients. Median progression-free survival with crizotinib
treatment was found 26.1 (95% Confidence interval [CI], 8.1-44.1) months. Median overall survival
was 35.2 (95% CI, 13.5-56.9) months. Treatment-related Grade 1-2 adverse effects were observed in 9
(42.9%) patients and Grade 3-4 adverse effects were detected in 1 (4.8%) patient. Clinicopathological
parameters affecting survival were evaluated; age (p=0.02) and liver metastasis (p=0.03) were defined as
prognostic parameters. ROS1 positivity rate (p=0.08) was not found to be a prognostic factor.
CONCLUSION
In patients with ROS1 fusion-positive metastatic NSCLC, crizotinib was shown to be both efficacious
and safe. We also found that in this patient group, age and the existence of liver metastases are prognostic
factors.